Health · 19 views
New targeted therapy shows promising early results in advanced pancreatic cancer
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today…
Summary
An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown promising early results when combined with standard first-line chemotherapy, according to research presented today at the ESMO Gastrointestinal Cancers Congress 2026. The phase I/II multicenter study, led by researchers from Dana-Farber Cancer Institute in Boston, evaluated zoldonrasib in patients with metastatic pancreatic cancer whose tumors carried a KRAS G12D mutation.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- ‘What’s the safest way to defrost chicken?’ We’re answering your food safety questionsContinue reading
- Black patients can face longer breast cancer care delays, study findsContinue reading
- Baby Aspirin Misses Mark for Primary Cardiovascular Prevention in CKDContinue reading
- GLP-1s May Interact With Psychiatry MedicationContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow